Generic acne gel put to the test in large trial
NCT ID NCT07469228
First seen Mar 17, 2026 · Last updated Jun 22, 2026 · Updated 13 times
Summary
This completed Phase 1 trial compared a generic tretinoin gel (0.04%) to the brand-name RETIN-A MICRO for treating acne vulgaris. Over 1,000 participants aged 12 to 40 with mild to moderate acne applied the gel daily for 12 weeks. The goal was to see if the generic version works just as well and is as safe as the original.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACNE VULGARIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Pharmaceutical Industries, Inc.
Hawthorne, New York, 10532, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tretinoin gel microsphere, 0.04%
What this could lead to
If successful, this could show that the generic tretinoin gel works as well as the brand-name version for treating acne.
What could go wrong
This is an early Phase 1 trial focused on equivalence, not a new breakthrough. Results may not confirm the generic is as effective or safe as the reference drug.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.